NCT05376423View on ClinicalTrials.gov

To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Esophageal Cancer
Interventions
BIOLOGICAL

OBI-833/OBI-821

OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER